Here’s your Cheat Sheet to the week in Dow 30 business news:
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Starbucks Corporation (NASDAQ:SBUX) will now attempt to be more ‘Chinese’ as it intends to have a rapid expansion in that country, according to the Wall Street Journal.
Merck & Co. (NYSE:MRK) and Endocyte (NASDAQ:ECYT) reported that the European Medicines Agency has accepted for review the marketing authorization application filings for the new investigational cancer candidate vintafolide and investigational companion diagnostic imaging agent etarfolatide, EC20, for the targeted treatment of patients with folate-receptor positive platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin. The European Commission has granted orphan drug status to both vintafolide and etarfolatide.
United Technologies Corporation’s (NYSE:UTX) Pratt & Whitney has won a contract from the United States Army through which to research and develop an Advanced Variable-Speed Power Turbine to meet the range and lift needs for current and future force rotorcraft. The AVSPOT program is an initiative by the U.S. Army’s Aviation Applied Technology Directorate who is working with NASA to develop turbine tech that improves efficiency, performance, and affordability of rotorcraft engines and to validate that tech in a laboratory environment by 2016.
Microsoft Corporation (NASDAQ:MSFT) will begin to charge a higher rate for a “user client-access license” on December 1st, according to a report from Monday night. This move indicates that businesses which employ more than one device with the popular Microsoft software will have to pay a higher price to run that software on multiple devices, according to ZDNet‘s Mary Jo Foley to Business Insider.